- Home
- CMMB vs STRR Comparison
CMMB vs STRR Comparison
Compare CMMB & STRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- STRR
- Stock Information
- Founded
- CMMB 2004
- STRR 1985
- Country
- CMMB Israel
- STRR United States
- Employees
- CMMB N/A
- STRR N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CMMB Health Care
- STRR Health Care
- Exchange
- CMMB Nasdaq
- STRR Nasdaq
- Market Cap
- CMMB 23.0M
- STRR 6.3M
- IPO Year
- CMMB N/A
- STRR N/A
- Fundamental
- Price
- CMMB $1.16
- STRR $1.95
- Analyst Decision
- CMMB Strong Buy
- STRR Strong Buy
- Analyst Count
- CMMB 2
- STRR 1
- Target Price
- CMMB $8.50
- STRR $5.00
- AVG Volume (30 Days)
- CMMB 182.4K
- STRR 9.6K
- Earning Date
- CMMB 08-20-2025
- STRR 08-12-2025
- Dividend Yield
- CMMB N/A
- STRR N/A
- EPS Growth
- CMMB N/A
- STRR N/A
- EPS
- CMMB N/A
- STRR N/A
- Revenue
- CMMB N/A
- STRR $57,165,000.00
- Revenue This Year
- CMMB N/A
- STRR $33.64
- Revenue Next Year
- CMMB N/A
- STRR $22.87
- P/E Ratio
- CMMB N/A
- STRR N/A
- Revenue Growth
- CMMB N/A
- STRR 34.33
- 52 Week Low
- CMMB $0.87
- STRR $1.72
- 52 Week High
- CMMB $2.55
- STRR $5.35
- Technical
- Relative Strength Index (RSI)
- CMMB 38.60
- STRR 43.68
- Support Level
- CMMB $1.17
- STRR $1.94
- Resistance Level
- CMMB $1.20
- STRR $2.00
- Average True Range (ATR)
- CMMB 0.05
- STRR 0.05
- MACD
- CMMB 0.00
- STRR 0.00
- Stochastic Oscillator
- CMMB 16.46
- STRR 16.67
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About STRR Star Equity Holdings Inc.
Star Equity Holdings Inc is a multi-industry diversified holding company. It operates in two segments: Building Solutions segment, through KBS, EBGL and TT, it services residential and commercial construction projects by manufacturing modular housing units, structural wall panels, permanent wood foundation systems, other engineered wood products, and supply general contractors with building materials; and Investments segment, which holds corporate-owned real estate, currently includes one manufacturing facility and the equipment for another manufacturing facility in Maine that it leases back to KBS and its manufacturing facility in Wisconsin that it leases back to TT. The company derives maximum revenue from Building Solutions Segment.